Home » BMS Submits New Treatment Regimen in Japan for Patients with Chronic Hepatitis C
BMS Submits New Treatment Regimen in Japan for Patients with Chronic Hepatitis C
Bristol-Myers Squibb announced the submission of a new drug application to Japan’s Pharmaceutical and Medical Devices Agency seeking the world’s first interferon-free and ribavirin-free treatment regimen for patients with chronic hepatitis C.
Bristol-Meyers Squibb
Bristol-Meyers Squibb
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May